Status:
COMPLETED
A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
To evaluate the efficacy of early intervention (dosing within 2 hours of onset of the migraine attack) with eletriptan 40mg on mild versus moderate to severe pain intensity of migraine.
Eligibility Criteria
Inclusion
- Diagnosis of migraine with or without aura according to the recent IHS criteria.
- Migraine headaches must have been present for more than one year.
- History in the last 3 months of 1 to 4 acute attacks of migraine headache per month.
Exclusion
- Subjects with current or past history of coronary artery disease.
- Pregnant or breastfeeding women.
- Subjects who have chronic daily headaches.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00174395
Start Date
March 1 2005
End Date
October 1 2006
Last Update
January 27 2021
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Edmonton, Alberta, Canada
2
Pfizer Investigational Site
Chilliwack, British Columbia, Canada
3
Pfizer Investigational Site
Coquitlam, British Columbia, Canada
4
Pfizer Investigational Site
Langley, British Columbia, Canada